The weak association with improved outcome with cilengitide in patients with glioblastoma lacking MGMT promoter methylation in the phase II CORE trial may justify patient enrichment based on αvβ3 expression in tumor cells in future trials. This evidence concerns the gene MGMT and glioblastoma.